公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2020 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements | Kudo M.; Han K.-H.; Ye S.-L.; Zhou J.; Huang Y.-H.; Lin S.-M.; Wang C.-K.; Ikeda M.; Chan S.L.; Choo S.P.; Miyayama S.; ANN-LII CHENG | Liver Cancer | 150 | 146 | |
2021 | Female leadership in oncology—has progress stalled? Data from the ESMO W4O authorship and monitoring studies | Berghoff A.S.; Sessa C.; CHIH-HSIN YANG ; Tsourti Z.; Tsang J.; Tabernero J.; Peters S.; Linardou H.; Letsch A.; Haanen J.; Garralda E.; Garassino M.C.; Furness A.J.S.; Felip E.; Dimopoulou G.; Dafni U.; Choo S.P.; Banerjee S.; Bajpai J.; Adjei A.A.; Garrido P. | ESMO Open | 10 | 5 | |
2019 | First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma | Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN ; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. | Cancer Discovery | 154 | 136 | |
2021 | Has COVID-19 had a greater impact on female than male oncologists? Results of the ESMO Women for Oncology (W4O) Survey | Garrido P.; Adjei A.A.; Bajpai J.; Banerjee S.; Berghoff A.S.; Choo S.P.; Felip E.; Furness A.J.S.; Garralda E.; Haanen J.; Letsch A.; Linardou H.; Peters S.; Sessa C.; Tabernero J.; Tsang J.; CHIH-HSIN YANG ; Garassino M.C. | ESMO Open | 16 | 14 | |
2020 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS–ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO | Chen L.-T.; Martinelli E.; ANN-LII CHENG ; Pentheroudakis G.; Qin S.; Bhattacharyya G.S.; Ikeda M.; Lim H.-Y.; Ho G.F.; Choo S.P.; Ren Z.; Malhotra H.; Ueno M.; Ryoo B.-Y.; Kiang T.C.; Tai D.; Vogel A.; Cervantes A.; Lu S.-N.; Yen C.-J.; Huang Y.-H.; Chen S.-C.; CHIUN HSU ; YING-CHUN SHEN ; Tabernero J.; Yen Y.; CHIH-HUNG HSU ; Yoshino T.; Douillard J.-Y. | Annals of Oncology | 117 | 112 | |
2018 | Phase II study of BGJ398 in patients with FGFR-Altered advanced cholangiocarcinoma | Javle M.; Lowery M.; Shroff R.T.; Weiss K.H.; Springfeld C.; Borad M.J.; Ramanathan R.K.; Goyal L.; Sadeghi S.; Macarulla T.; El-Khoueiry A.; Kelley R.K.; Borbath I.; Choo S.P.; Oh D.-Y.; Philip P.A.; Chen L.-T.; Reungwetwattana T.; Van Cutsem E.; KUN-HUEI YEH ; Ciombor K.; Finn R.S.; Patel A.; Sen S.; Porter D.; Isaacs R.; Zhu A.X.; Abou-Alfa G.K.; Bekaii-Saab T. | Journal of Clinical Oncology | 511 | 428 | |
2019 | A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma | Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN ; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. | Therapeutic Advances in Medical Oncology | 38 | 38 | |
2018 | SIRveNIB: Selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma | Chow P.K.H.; Gandhi M.; Tan S.-B.; Khin M.W.; Khasbazar A.; Ong J.; Choo S.P.; Cheow P.C.; Chotipanich C.; Lim K.; Lesmana L.A.; Manuaba T.W.; Yoong B.K.; Raj A.; Law C.S.; Cua I.H.Y.; Lobo R.R.; Teh C.S.C.; Kim Y.H.; Jong Y.W.; Han H.-S.; Bae S.-H.; Yoon H.-K.; Lee R.-C.; Hung C.-F.; Peng C.-Y.; PO-CHIN LIANG ; Bartlett A.; Kok K.Y.Y.; Thng C.-H.; Low A.S.-C.; Goh A.S.W.; Tay K.H.; Lo R.H.G.; Goh B.K.P.; Ng D.C.E.; Lekurwale G.; Liew W.M.; Gebski V.; Mak K.S.W.; Soo K.C. | Journal of Clinical Oncology | 445 | 394 |